Replies to post #230 on Evolus (EOLS)

[boraborak38]

Jeuveau hitting its stride and taking share.

[DewDiligence]

EOLS 2Q23 results—6/30/23 cash=$41.7M:

https://investors.evolus.com/press-releases-and-news/news-details/2023/Evolus-Reports-Second-Quarter-2023-Results-and-Provides-Business-Update/default.aspx

Cash and cash equivalents at June 30, 2023 were $41.7 million compared to $31.5 million at March 31, 2023. The cash balance at June 30, 2023 included additional borrowings of $25 million under the company’s credit facility with Pharmakon. For the second quarter of 2023, net cash used for operating activities was $13.3 million, which included the $4.4 million license milestone expense.

EOLS pre-announced 2Q23 sales of $49.3M last week (#msg-172453778).

[DewDiligence]

EOLS reports 3Q23 results:

https://investors.evolus.com/press-releases-and-news/news-details/2023/Evolus-Reports-Record-Third-Quarter-2023-Financial-Results-and-Phase-II-Data-for-Extra-Strength-40U-Formulation-of-Jeuveau/default.aspx

3Q23 Jeuveau sales were $49.3M, +1% QoQ and +48% YoY.

3Q23 GAAP net income (loss) was ($17.0M) or ($0.30)/sh.

Cash at 9/30/23 was $38.7M, down from $41.7M at 6/30/23.

EOLS increased 2023 revenue guidance to $194-198M (from the prior range of $185-195M).